Kanchan K Banerjee: Rusfertide Earns NCCN Category 1 Recommendation for Polycythemia Vera
Kanchan K Banerjee, Director of Strategy and Growth at WEbRx Lifesystems India Private Limited, shared a post on LinkedIn:
“Rusfertide Earns NCCN Category 1 in Polycythemia Vera: What the Update Signals
Takeda announced on September 21 that rusfertide (Mimrylo™), FDA-approved on August 28, 2026, has been included as a Category 1 option across both low- and high-risk PV in the NCCN Guidelines for Myeloproliferative Neoplasms. It is the only therapy carrying Category 1 status across both risk groups.
The eviden ce base (Phase 3 VERIFY, NCT05210790)
▪ Population: phlebotomy-dependent patients with uncontrolled hematocrit
▪ Clinical response (weeks 20-32): 76.9 percent with rusfertide + standard of care vs 32.9 percent with placebo + SOC (P < .0001)
▪ Key secondary endpoints, including phlebotomy burden, hematocrit <45 percent and fatigue, were met
▪ Most common adverse events: injection site reactions (47.4 percent) and anemia (25.6 percent)
Rusfertide sits alongside standard hematocrit-directed care, and treatment decisions remain with treating clinicians.
Strategic note: The view from the marketing desk
Guideline inclusion opens the door; it does not drive adoption on its own. Where to focus:
- Science first: lead with trial design, population and safety, including anemia.
- Precise patient definition: keep every asset anchored to the phlebotomy-dependent profile studied in VERIFY.
- Whole care team: phlebotomy nurses, clinic coordinators and pharmacists shape the pathway, so plan education for them alongside physician engagement.
- Access and patient support: with most spending out of pocket, in India, plan for affordability, access programs, patient education and counselling that supports injection technique and adherence
Swipe through the carousel for the clinical detail.
Views are my own. Please refer to the full prescribing information.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines